Graphite Capital has agreed the sale of life sciences data and workflow platform Beacon to Corten Capital, in a deal that is expected to deliver of 4x cash return on the firm’s original investment in Hanson Wade in 2019.
Beacon, which provides decision-support tools used by pharmaceutical and biotech companies to guide research and development investment, was carved out of Hanson Wade. The platform is used by senior scientists across global life sciences organisations and serves more than 300 cu...
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.